Veeva Systems Inc. $VEEV Shares Newly Acquired by United Advisor Group LLC

United Advisor Group LLC bought a new stake in Veeva Systems Inc. (NYSE:VEEV) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,975 shares of the technology company’s stock, valued at approximately $564,000.

Other institutional investors have also added to or reduced their stakes in the company. Czech National Bank bought a new stake in Veeva Systems in the 2nd quarter valued at $7,584,000. Vulcan Value Partners LLC acquired a new position in shares of Veeva Systems in the 2nd quarter valued at $3,769,000. Westwind Capital acquired a new position in shares of Veeva Systems in the 3rd quarter valued at $1,684,000. East Coast Asset Management LLC. acquired a new position in shares of Veeva Systems in the 1st quarter valued at $1,665,000. Finally, First Citizens Bank & Trust Co. bought a new position in shares of Veeva Systems during the 3rd quarter worth about $1,179,000. 88.20% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $365 from $325 and reiterated an “outperform” rating, implying about 20% upside from the cited $304.23 share price. Royal Bank of Canada recommendations
• Positive Sentiment: Needham raised its target to $360 from $310 and maintained a “buy” rating, citing about 18% potential upside from $304.23. Needham recommendations
• Positive Sentiment: Stifel lifted its price target to $340 from $300, adding to the wave of upward target revisions. Stifel raises Veeva price target
• Positive Sentiment: UCB selected Veeva Vault CRM as a core platform for its commercial operations and plans to use industry-specific AI for product launches and customer engagement. The deal supports Veeva’s positioning as a specialized technology provider for life sciences companies. Veeva becomes core CRM choice for major biopharma AI rollout

Analyst Ratings Changes

A number of brokerages have commented on VEEV. BNP Paribas Exane raised their price target on shares of Veeva Systems from $285.00 to $300.00 in a research note on Thursday, August 27th. Mizuho set a $345.00 price objective on Veeva Systems in a research note on Thursday, October 29th. Truist Financial raised their target price on Veeva Systems from $262.00 to $305.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. The Goldman Sachs Group upped their price target on Veeva Systems from $165.00 to $180.00 in a research report on Thursday, August 27th. Finally, Evercore upped their target price on shares of Veeva Systems from $185.00 to $250.00 in a report on Thursday, October 8th. Nineteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $309.08.

Insider Buying and Selling at Veeva Systems

In other news, SVP Jonathan Faddis sold 5,198 shares of Veeva Systems stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $299.72, for a total transaction of $1,557,944.56. Following the completion of the sale, the senior vice president owned 4,130 shares in the company, valued at $1,237,843.60. The trade was a 55.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Priscilla Hung sold 750 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total transaction of $195,780.00. Following the completion of the transaction, the director owned 3,242 shares in the company, valued at $846,291.68. This represents a 18.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 56,789 shares of company stock worth $14,913,889 in the last 90 days. Corporate insiders own 10.60% of the company’s stock.

Veeva Systems Trading Up 0.2%

Shares of NYSE VEEV opened at $304.23 on Monday. Veeva Systems Inc. has a 1-year low of $148.05 and a 1-year high of $325.99. The company has a 50-day moving average of $289.24 and a two-hundred day moving average of $211.95. The company has a market cap of $49.26 billion, a PE ratio of 50.04, a P/E/G ratio of 1.30 and a beta of 0.89.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.23 by $0.12. The company had revenue of $927.96 million during the quarter, compared to analysts’ expectations of $905.38 million. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%. The business’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same period last year, the firm earned $1.99 EPS. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. As a group, equities research analysts forecast that Veeva Systems Inc. will post 6.70 earnings per share for the current year.

About Veeva Systems

Veeva Systems Inc develops cloud-based software, data and consulting services for the life sciences industry. Its customers include pharmaceutical and biotechnology companies, medical device makers and contract research organizations.

The company’s products support commercial operations as well as clinical, regulatory, quality and safety activities. Its offerings include Veeva Vault applications for managing documents and business processes, customer relationship management software, and data and analytics services.

Founded in 2007 and headquartered in Pleasanton, California, Veeva serves life sciences companies in markets around the world.